| [1] |
Wein AJ. Re: International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary tract function [J]. J Urol, 2019, 202(4): 665-666.
|
| [2] |
Weiss JP. Nocturia: "do the math" [J]. J Urol, 2006, 175(3 Pt 2): S16-S18.
|
| [3] |
Weiss JP, Blaivas JG, Bliwise DL, et al. The evaluation and treatment of nocturia: a consensus statement [J]. BJU Int, 2011, 108(1): 6-21.
|
| [4] |
Schneider T, de la Rosette JJ, Michel MC. Nocturia: a non-specific but important symptom of urological disease [J]. Int J Urol, 2009, 16(3): 249-256.
|
| [5] |
Choo MS, Ku JH, Park CH, et al. Prevalence of nocturia in a Korean population aged 40 to 89 years [J]. Neurourol Urodyn, 2008, 27(1): 60-64.
|
| [6] |
Liew LC, Tiong HY, Wong ML, et al. A population study of nocturia in Singapore [J]. BJU Int, 2006, 97(1): 109-112.
|
| [7] |
Fitzgerald MP, Litman HJ, Link CL, et al. The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey [J]. J Urol, 2007, 177(4): 1385-1389.
|
| [8] |
Tikkinen KA, Auvinen A, Johnson TM 2nd, et al. A systematic evaluation of factors associated with nocturia--the population-based FINNO study [J]. Am J Epidemiol, 2009, 170(3): 361-368.
|
| [9] |
Fu Z, Wang F, Dang X, et al. The association between diabetes and nocturia: a systematic review and meta-analysis [J]. Front Public Health, 2022, 10: 924488.
|
| [10] |
Abrams P, Andersson KE, Apostolidis A, et al. 6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence [J]. Neurourol Urodyn, 2018, 37(7): 2271-2272.
|
| [11] |
Van Kerrebroeck P, Andersson KE. Terminology, epidemiology, etiology, and pathophysiology of nocturia [J]. Neurourol Urodyn, 2014, 33(Suppl 1): S2-S5.
|
| [12] |
Gordon DJ, Emeruwa CJ, Weiss JP. Management strategies for nocturia [J]. Curr Urol Rep, 2019, 20(11): 75.
|
| [13] |
Gulur DM, Mevcha AM, Drake MJ. Nocturia as a manifestation of systemic disease [J]. BJU Int, 2011, 107(5): 702-713.
|
| [14] |
Brown JS, Wessells H, Chancellor MB, et al. Urologic complications of diabetes [J]. Diabetes Care, 2005, 28(1): 177-185.
|
| [15] |
Bansal R, Agarwal MM, Modi M, et al. Urodynamic profile of diabetic patients with lower urinary tract symptoms: association of diabetic cystopathy with autonomic and peripheral neuropathy [J]. Urology, 2011, 77(3): 699-705.
|
| [16] |
Victor RG, Li N, Blyler CA, et al. Nocturia as an unrecognized symptom of uncontrolled hypertension in black men aged 35 to 49 years [J]. J Am Heart Assoc, 2019, 8(5): e010794.
|
| [17] |
Cho MC, Ku JH, Paick JS. Alpha-blocker plus diuretic combination therapy as second-line treatment for nocturia in men with LUTS: a pilot study [J]. Urology, 2009, 73(3): 549-553.
|
| [18] |
Paschou SA, Bletsa E, Saltiki K, et al. Sleep apnea and cardiovascular risk in patients with prediabetes and type 2 diabetes [J]. Nutrients, 2022, 14(23)：4989.
|
| [19] |
Guilleminault C, Lin CM, Gonçalves MA, et al. A prospective study of nocturia and the quality of life of elderly patients with obstructive sleep apnea or sleep onset insomnia [J]. J Psychosom Res, 2004, 56(5): 511-515.
|
| [20] |
Andersson KE, Van Kerrebroeck P. Pharmacotherapy for nocturia [J]. Curr Urol Rep, 2018, 19(1): 8.
|
| [21] |
Suman S, Robinson D, Bhal N, et al. Management of nocturia: overcoming the challenges of nocturnal polyuria [J]. Br J Hosp Med (Lond), 2019, 80(9): 517-524.
|
| [22] |
Everaert K, Hervé F, Bosch R, et al. International Continence Society consensus on the diagnosis and treatment of nocturia [J]. Neurourol Urodyn, 2019, 38(2): 478-498.
|
| [23] |
Gravas S, Gacci M, Gratzke C, et al. Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms [J]. Eur Urol, 2023, 84(2): 207-222.
|
| [24] |
Przydacz M, Chlosta M, Dudek P, et al. Desmopressin treatment for nocturia caused by nocturnal polyuria: practical guidelines [J]. Cent European J Urol, 2020, 73(4): 498-505.
|
| [25] |
Chung E. Desmopressin and nocturnal voiding dysfunction: clinical evidence and safety profile in the treatment of nocturia [J]. Expert Opin Pharmacother, 2018, 19(3): 291-298.
|
| [26] |
Weiss JP, Zinner NR, Klein BM, et al. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial [J]. Neurourol Urodyn, 2012, 31(4): 441-447.
|
| [27] |
Sand PK, Dmochowski RR, Reddy J, et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study [J]. J Urol, 2013, 190(3): 958-964.
|
| [28] |
Weiss JP, Herschorn S, Albei CD, et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study [J]. J Urol, 2013, 190(3): 965-972.
|
| [29] |
Yamaguchi O, Juul KV, Falahati A, et al. Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program [J]. Low Urin Tract Symptoms, 2020, 12(1): 8-19.
|
| [30] |
Suvada K, Plantinga L, Vaughan CP, et al. Comorbidities, age, and polypharmacy limit the use by US older adults with nocturia of the only FDA-approved drugs for the symptom [J]. Clin Ther, 2020, 42(12): e259-e274.
|
| [31] |
Kaminetsky J, Fein S, Dmochowski R, et al. Efficacy and safety of SER120 nasal spray in patients with nocturia: pooled analysis of 2 randomized, double-blind, placebo controlled, phase 3 trials [J]. J Urol, 2018, 200(3): 604-611.
|
| [32] |
Monaghan TF, Bliwise DL, Denys MA, et al. Phenotyping nocturnal polyuria: circadian and age-related variations in diuresis rate, free water clearance and sodium clearance [J]. Age Ageing, 2020, 49(3): 439-445.
|
| [33] |
Monaghan TF, Epstein MR, Bliwise DL, et al. Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome [J]. Neurourol Urodyn, 2020, 39(2): 785-792.
|
| [34] |
Monaghan TF, Suss NR, Epstein MR, et al. Differential nocturnal diuresis rates among patients with and without nocturnal polyuria syndrome [J]. Eur Urol Focus, 2020, 6(2): 320-326.
|
| [35] |
Dani H, Esdaille A, Weiss JP. Nocturia: aetiology and treatment in adults [J]. Nat Rev Urol, 2016, 13(10): 573-583.
|
| [36] |
Wisniewski K, Qi S, Kraus J, et al. Discovery of potent, selective, and short-acting peptidic V2 receptor agonists [J]. J Med Chem, 2019, 62(10): 4991-5005.
|